CBAY News and Press, CymaBay Therapeutics Inc. From 03/23/23

2023-03-23 17:01:12 ET Gainers: Pyxis Oncology ( PYXS ) +15% . CRISPR Therapeutics ( CRSP ) +11% . ADMA Biologics ( ADMA ) +6% . Harrow Health ( HROW ) +4% . Solid Power ( SLDP ) +5% . Losers: Scholastic ( SCHL ) -1...

2023-03-16 20:43:08 ET CymaBay Therapeutics, Inc. (CBAY) Q4 2022 Earnings Conference Call March 16, 2023 4:30 P.M. ET Company Participants Paul Quinlan - General Counsel Sujal Shah - Chief Executive Officer Chuck McWherter - President, Research & Development ...

2023-03-16 16:08:47 ET CymaBay Therapeutics press release ( NASDAQ: CBAY ): Q4 GAAP EPS of -$0.30 misses by $0.01 . Held $135.5 million in cash, cash equivalents and investments as of December 31, 2022. For further details see: CymaBay Therapeutics GAAP EPS o...

NEWARK, Calif., March 16, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the year ...

NEWARK, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio we...

NEWARK, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the Oppenheimer 3...

Summary CymaBay caught a strong bid in early FY23 after advising its collaboration with Kaken Pharma in Japan. Its seladelpar compound has potential to create a medical breakthrough in primary biliary cholangitis. This could disrupt the current treatment paradigm and enable CBAY to ...

NEWARK, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that management will participate in the SVB Securities...

NEWARK, Calif., Jan. 30, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need announced the closing, on January 26, 2023, of its previously a...

CymaBay Therapeutics ( NASDAQ: CBAY ) announces the pricing the previously announced public offering of common stock and pre-funded warrants. The company to sell 10M shares of common stock and pre-funded warrants to purchase 2,142,857 shares of common stock in the offering. ...